Leerink Partnrs Issues Negative Outlook for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will earn ($0.52) per share for the quarter, down from their previous estimate of ($0.51). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($2.06) EPS.

Other analysts have also recently issued research reports about the stock. Sanford C. Bernstein dropped their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Chardan Capital restated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $43.33.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $21.53 on Friday. The company has a fifty day simple moving average of $20.69 and a 200-day simple moving average of $22.07. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $36.72.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 32,729 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the sale, the insider now directly owns 272,122 shares of the company’s stock, valued at $5,393,458.04. This represents a 10.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the sale, the director now owns 36,740 shares in the company, valued at approximately $734,800. This trade represents a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 146,473 shares of company stock worth $2,937,847. 4.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. World Investment Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after buying an additional 700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock worth $1,199,000 after purchasing an additional 886 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of Arrowhead Pharmaceuticals by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 14,417 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 980 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Arrowhead Pharmaceuticals by 5.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,262 shares of the biotechnology company’s stock valued at $586,000 after purchasing an additional 1,523 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.